Strides Pharma Science share news, announcements and annual reports
NSE: STARBSE: 532531Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 2 Nov 2026. Previous close ₹1,068.80.
2 Nov: open ₹1,067.30, high ₹1,067.30, low ₹1,013.90
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹9,557 Cr580th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 15.50
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.80
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.48%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 20.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 13.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.53
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 4,07,98637.7% delivered
Strides Pharma Science share news and announcements
1,447 announcements, routine notices left out, newest first. Page 3 of 29.
May 2025
15 May · General Updates
15 May · Analysts
10 May · General Updates
Apr 2025
29 Apr · General Updates
11 Apr · Incorporation
1 Apr · General Updates
Mar 2025
19 Mar · General Updates
18 Mar · General Updates
Feb 2025
17 Feb · Meeting
Jan 2025
30 Jan · Results
30 Jan · Address Change
30 Jan · Management
30 Jan · Board meeting
24 Jan · Analysts
24 Jan · Board meeting
Dec 2024
11 Dec · Business
11 Dec · Business
Nov 2024
26 Nov · Corporate action
25 Nov · General Updates
Oct 2024
28 Oct · Meeting
25 Oct · Business
24 Oct · Business
24 Oct · Management
24 Oct · Results
18 Oct · Analysts
18 Oct · Board meeting
8 Oct · Updates
1 Oct · General Updates
Sep 2024
26 Sep · Meeting